The NHS Sickle Cell and Thalassaemia (SCT) screening programme is a genetic screening programme. This means that it also identifies people who are genetic carriers for sickle cell, thalassaemia and other haemoglobin disorders.
As the numbers of people infected by the COVID-19 steadily increases in the UK, we would like to provide you with advice on how to protect you and your family from contracting the virus and the steps you need to follow if you feel you have contracted the virus.
The following information was provided to us by the Department of Health, Professors, Consultant Haematologists and Clinical Nurse Specialists at various centres of excellence in thalassaemia and Sickle Cell care in London.
West Midlands Quality Review Service is a collaborative venture by NHS organisations in the West Midlands to improve the quality of health services by undertaking reviews of the quality of clinical services.
The National Haemoglobinopathy Registry is a database of patients with red cell disorders living in the UK. This new database collects data,which is required by the Department of Health from Haemoglobinopathy centres. The central aim of the registry is to improve patient care.
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. Our guidance, advice, quality standards and information services for health, public health and social care. Also contains resources to help maximise use of evidence and guidance
This Clinical Reference Group (CRG) covers Sickle Cell Disease (SCD), Thalassaemia and other very rare anaemias requiring lifelong transfusion and chelation. Haemoglobinopathies are complex disorders which although often grouped together and managed by the same specialist team, have distinct clinical manifestations and treatments.